<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00297882</url>
  </required_header>
  <id_info>
    <org_study_id>ITCRVG46</org_study_id>
    <nct_id>NCT00297882</nct_id>
  </id_info>
  <brief_title>Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon</brief_title>
  <official_title>Phase III Clinical Trials of Artemisinin-based Combination Therapy in Cameroon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Yaounde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cameroon Baptist Convention Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal aims to evaluate the safety and efficacy of artemisinin-based anti-malaria&#xD;
      combination drugs (ACTs) for the treatment of children aged 6-120 months in different&#xD;
      locations in Cameroon. Randomized clinical trials will provide local data on the safety of&#xD;
      the test drugs, and on putative marker mutations of the development of resistance to ACT. The&#xD;
      study will involve three centers, namely, Banso (Guinea-Savannah region), Limbe(Littoral&#xD;
      Forest), and Garoua(Sahel-Savannah). The trial will compare the efficacy and safety of&#xD;
      Amodiaquine(AQ)-Artesunate(Art) with Coartem®(Artemether-Lumefantrine). Drug efficacy will be&#xD;
      determined using a WHO standardized 28-day protocol. Safety will be monitored through&#xD;
      clinical examination and biochemical and hematological indices. Molecular markers of&#xD;
      artemisinin resistance will be investigated by molecular sequencing and comparison of&#xD;
      parasite profiles of the PfATP6 gene in drug failure cases, . Recrudescences or re-infections&#xD;
      will be assessed by analysis of the msp1 and msp2 genes. The impact of these combinations on&#xD;
      generation of gametocytes will be determined from gametocyte carriage rates measured by&#xD;
      microscopy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Outpatients will be screened for malaria by blood film examination&#xD;
&#xD;
        -  Malaria-positive children will be examined by the physician for inclusion or&#xD;
           exclusion(see below)&#xD;
&#xD;
        -  Informed consent will be sought from the guardians of potential patients&#xD;
&#xD;
        -  Patients or guardians will be interviewed and a case record form completed&#xD;
&#xD;
        -  Patients will be randomized into one of the two arms in the ratio 4:1 AQ/Art: CoArtem&#xD;
           and issued a study card&#xD;
&#xD;
        -  Filter paper and 5ml venous blood samples will be collected&#xD;
&#xD;
        -  Patients will be hospitalised for three days to allow completion of therapy under&#xD;
           observation&#xD;
&#xD;
        -  The patient will be asked to return on days 7, 14 and 28 for assessment of clearance or&#xD;
           recrudescence of parasites&#xD;
&#xD;
        -  Patient will be examined for parasites and evaluated for early treatment failure (ETF),&#xD;
           late treatment failure (LTF), late parasitological failure (LPF) or adequate clinical&#xD;
           and parasitological response.(ACPR).&#xD;
&#xD;
        -  If a patient does not appear for follow up, a community health worker will try to trace&#xD;
           them and will collect blood onto filter paper and a microscope slide should the patient&#xD;
           have a temperature ≥ 37.5°C&#xD;
&#xD;
        -  Patients whose parents opt out of the study will be administered quinine sulphate if&#xD;
           parasitaemic&#xD;
&#xD;
        -  Filter paper samples will be air dried and stored with dessicant until required.&#xD;
&#xD;
        -  Whole blood samples collected into citrate as anticoagulant will be processed for&#xD;
           plasma, aliquoted into 300µl lots and stored at -70°C.&#xD;
&#xD;
        -  Patient information will be entered at the close of each day into laptops and&#xD;
           collectively sent to Yaounde at the end of the first month of study and thereafter at&#xD;
           the end of each week, along with the hard copies of the case report forms.&#xD;
&#xD;
        -  Analysis will be performed on the samples within three months of collection for&#xD;
           molecular markers of resistance, genetic structure of parasites and for blood drug&#xD;
           levels of medications used in the trial&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure Rate on Day 28</measure>
    <time_frame>Day 0 - 28</time_frame>
    <description>To evaluate the safety and antimalarial efficacy of two drug combinations: Artemether-Lumefantrine (AL) and Amodiaquine-Artesunate (AQ - AS) in Camaroonian patients in Mutengene, Bangolan and Garoua</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cure Rate Day 14</measure>
    <time_frame>Day 0-14</time_frame>
    <description>To evaluate antimalarial efficacy of AL and AQ-AS on day 14 post-treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">816</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>1 Artemether-Lumefantrine (AL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study group 1. Subjects in this group received treatment with Artemether-Lumefantrine. Children received 2 mg/kg Artemether and 12 mg/kg Lumefrantrine with milk twice daily (or every 12 hours for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Amodiaquine-Artesunate (AQ-AS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study group 2. Subjects in this group received treatment with Amodiaquine-Artesunate. Children received a co-administered combination of 30 mg/kg Amodiaquine (AQ) plus 4 mg/kg Artesunate (AS) daily for 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1. Artemether-Lumefantrine (AL)</intervention_name>
    <description>Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).</description>
    <arm_group_label>1 Artemether-Lumefantrine (AL)</arm_group_label>
    <other_name>CoArtem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2. Amodiaquine-Artesunate (AQ-AS)</intervention_name>
    <description>Amodiaquine-Artesunate (0H),D1(24H),D2(48H)= Artesunate 4mg/kg and Amodiaquine at 10mg/kg</description>
    <arm_group_label>2 Amodiaquine-Artesunate (AQ-AS)</arm_group_label>
    <other_name>Arsucam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  children aged 6-120 months;&#xD;
&#xD;
          -  axillary temperature ≥ 37.5°C and/or history of fever within past 24 hours;&#xD;
&#xD;
          -  P. falciparum asexual parasitemia between 1000 and 100000/µl;&#xD;
&#xD;
          -  ability to attend follow-up visits.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  co-infections;&#xD;
&#xD;
          -  underlying chronic disease;&#xD;
&#xD;
          -  severe malaria as indicated by hyperparasitemia, severe anemia (PCV 15%, Hb 5g/ml),&#xD;
             respiratory distress, inability to drink, persistent vomiting in past 24 hours;&#xD;
&#xD;
          -  recent history of multiple convulsions;&#xD;
&#xD;
          -  jaundice;&#xD;
&#xD;
          -  the inability to stand or sit;&#xD;
&#xD;
          -  history of allergy to study drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>120 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilfred F Mbacham, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Yaounde</affiliation>
  </overall_official>
  <removed_countries>
    <country>Cameroon</country>
  </removed_countries>
  <link>
    <url>http://www.gatesmalariapartnership.org/</url>
    <description>(Gates Malaria Partnership)</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 28, 2006</study_first_submitted>
  <study_first_submitted_qc>February 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2006</study_first_posted>
  <results_first_submitted>May 23, 2017</results_first_submitted>
  <results_first_submitted_qc>May 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 8, 2021</results_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>London School of Hygiene and Tropical Medicine</investigator_affiliation>
    <investigator_full_name>Brian Greenwood</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Children</keyword>
  <keyword>Cameroon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemether, Lumefantrine Drug Combination</mesh_term>
    <mesh_term>Amodiaquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Database available on request of Prof Wilfred Mbacham wfmbacham@yahoo.com</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>2013 and for 10 years</ipd_time_frame>
    <ipd_access_criteria>Database available on reqeust of Prof Wilfred Mbacham wfmbacham@yahoo.com</ipd_access_criteria>
    <ipd_url>https://www.gatesmalariapartnership.org/</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eight hundred and sixteen children aged 6-120 months with uncomplicated falciparum malaria were studied in three ecological different regions of Cameroon - Mutengene (Littoral equatorial forest), Bangolan (Rice farming guinea-savanna) and Garoua (Guinea-savannah).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Artemether-Lumefantrine</title>
          <description>Drug: Artemether-Lumefantrine, Artemether-Lumefantrine(Co-Artem) =Artemether, 2mg/kg x 2 (12H apart)/Lumefantrine, 12mg/kgx2 (12H apart).&#xD;
Other Names: • CoArtem,</description>
        </group>
        <group group_id="P2">
          <title>2 Amodiaquine- Artesunate</title>
          <description>Drug: Amodiaquine-Artesunate Amodiaquine-Artemether - administration D0 (0H), D1 (24H), D2 (48H)- Artesunate 4mg/kg &amp; Amodiaquine at 10mg/kg Other Names: • Arsucam</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Day 14</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="612"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="563"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Day 28</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="563"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="540"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Artemether-Lumefantrine</title>
          <description>Artemether-Lumefantrine , Amodiaquine-Artesunate: 1 Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).&#xD;
2 Amodiaquine-ArtemetherD0(0H),D1(24H),D2(48H)- Artesunate 4mg/kg and Amodiaquine at 10mg/kg</description>
        </group>
        <group group_id="B2">
          <title>2 Amodiaquine-Artemether</title>
          <description>Artemether-Lumefantrine , Amodiaquine-Artesunate: 1 Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).&#xD;
2 Amodiaquine-ArtemetherD0(0H),D1(24H),D2(48H)- Artesunate 4mg/kg and Amodiaquine at 10mg/kg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="204"/>
            <count group_id="B2" value="612"/>
            <count group_id="B3" value="816"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>100 did not complete the trial including 4 deaths</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.87" spread="28.4"/>
                    <measurement group_id="B2" value="50.77" spread="27.33"/>
                    <measurement group_id="B3" value="51.82" spread="27.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>100 did not complete trial, including 4 deaths</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="406"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="310"/>
                    <measurement group_id="B3" value="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Cameroon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="612"/>
                    <measurement group_id="B3" value="816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cure Rate on Day 28</title>
        <description>To evaluate the safety and antimalarial efficacy of two drug combinations: Artemether-Lumefantrine (AL) and Amodiaquine-Artesunate (AQ - AS) in Camaroonian patients in Mutengene, Bangolan and Garoua</description>
        <time_frame>Day 0 - 28</time_frame>
        <population>Children aged 6 months-10 years in different locations in Cameroon.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Artemether-Lumefantrine AL</title>
            <description>1Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).</description>
          </group>
          <group group_id="O2">
            <title>2 Amodiaquine-Artesunate AQ-AS</title>
            <description>2 Amodiaquine-Artesunate 4mg/kg and Amodiaquine at 10mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Cure Rate on Day 28</title>
          <description>To evaluate the safety and antimalarial efficacy of two drug combinations: Artemether-Lumefantrine (AL) and Amodiaquine-Artesunate (AQ - AS) in Camaroonian patients in Mutengene, Bangolan and Garoua</description>
          <population>Children aged 6 months-10 years in different locations in Cameroon.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197"/>
                    <measurement group_id="O2" value="603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample Size will be determined by N = {[(Zα/2)/E]*2}pq where Where: n=sample size; Zα/2= Z value of a two-tailed test with 95% confidence level=1.96; p represents cure rate, q=1-p, which represents treatment failure rate of; E=precision of 5%</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of AQ-AS compared to AL was assessed by constructing a one-sided, lower limit asymptotic 97.5% CI on the difference of polymerase chain reaction (PCR)-corrected cure rates of AQ-AS when compared to AL. Non-inferiority was declared if the lower limit of the CI was greater than -10% for AQ-AS.</non_inferiority_desc>
            <p_value>&gt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cure Rate Day 14</title>
        <description>To evaluate antimalarial efficacy of AL and AQ-AS on day 14 post-treatment</description>
        <time_frame>Day 0-14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Artemether-Lumefantrine</title>
            <description>1Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).</description>
          </group>
          <group group_id="O2">
            <title>2 Amodiaquine-Artesunate</title>
            <description>2 Amodiaquine-Artesunate 4mg/kg and Amodiaquine at 10mg/kg every day for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Cure Rate Day 14</title>
          <description>To evaluate antimalarial efficacy of AL and AQ-AS on day 14 post-treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample Size will be determined by N = {[(Zα/2)/E]*2}pq where Where: n=sample size; Zα/2= Z value of a two-tailed test with 95% confidence level=1.96; p represents cure rate, q=1-p, which represents treatment failure rate of; E=precision of 5%</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of AQ-AS compared to AL was assessed by constructing a one-sided, lower limit asymptotic 97.5% CI on the difference of polymerase chain reaction (PCR)-corrected cure rates of AQ-AS when compared to AL. Non-inferiority was declared if the lower limit of the CI was greater than -10% for AQ-AS.</non_inferiority_desc>
            <p_value>&gt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days following treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 Artemether-Lumefantine (AL)</title>
          <description>Study group 1. Subjects in this group received treatment with Artemether-Lumefantrine. Children received 2 mg/kg Artemether and 12 mg/kg Lumefrantrine with milk twice daily (or every 12 hours for 3 days.</description>
        </group>
        <group group_id="E2">
          <title>2 Amodiaquine-Artesunate (AQ-AS)</title>
          <description>Study group 2. Subjects in this group received treatment with Amodiaquine-Artesunate. Children received a co-administered combination of 30 mg/kg Amodiaquine (AQ) plus 4 mg/kg Artesunate (AS) daily for 3 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="612"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="612"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="612"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="612"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Event leading to death</sub_title>
                <description>Malaria</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="612"/>
              </event>
              <event>
                <sub_title>Blackwater fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="612"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="272" subjects_at_risk="612"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="204"/>
                <counts group_id="E2" events="139" subjects_affected="139" subjects_at_risk="612"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="204"/>
                <counts group_id="E2" events="93" subjects_affected="93" subjects_at_risk="612"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="204"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="612"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="204"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="612"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="204"/>
                <counts group_id="E2" events="63" subjects_affected="63" subjects_at_risk="612"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="204"/>
                <counts group_id="E2" events="123" subjects_affected="123" subjects_at_risk="612"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="204"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="612"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="204"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="612"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="612"/>
              </event>
              <event>
                <sub_title>Cuteneous eruptions</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="612"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no limitations or caveats that prevented completion of the trial as planned</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Professor Wilfred Mbacham</name_or_title>
      <organization>University of Yaounde 1, Cameroon</organization>
      <phone>+237 677579180</phone>
      <email>wfmbacham@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

